StreetAlpha.app
Home › Stocks › ALZN

Alzamend Neuro, Inc. (ALZN)

$1.13
▼ −4.24%
LAST CLOSE · NOV 17

Alzamend Neuro is a clinical stage drug developer in Atlanta working on treatments for Alzheimer's and other brain disorders. It last closed at $1.13 on Nov 17, down 4.24% on the day. ALZN reports earnings on Tue, Dec 8, 2026.

AI Auto Pilots
Is ALZN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$9.1M
EPS (diluted)
−$2.03
Valuation
Market cap
$5.5M
4.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$7.6M
At Jul 31
Shareholder equity
$5.8M
Shares outstanding
4.8M
At Sep 10
Fiscal year endsApril
ExchangeNasdaq
Financials history
FY2022: −$12.4M−$12.4MFY2022FY2023: −$14.9M−$14.9MFY2023FY2024: −$9.9M−$9.9MFY2024FY2025: −$4.5M−$4.5MFY2025FY2026: −$8.8M−$8.8MFY2026

From ALZN's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 10). Last 12 months adds up the four latest quarters.

Next report
Dec 8
2026 · Time not announced
Consensus EPS forecast
-$0.23
 
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated ALZN in the past 90 days.
Average 12-month target
No price targets on ALZN in the past 90 days.
Latest rating changes
Ascendiant CapitalMaintained
Aug 19Buy$26
DateFirmActionRatingPrice target
Aug 19Ascendiant CapitalMaintainedBuy$26
Loading…

Technical Analysis

ALZN · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 13% below its 20 day and 30% below its 50 day average. It is 26% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $1.10, and the nearest resistance the Pivot at $1.14.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 11.9%/day
Key levels
$2.5652 week high+126.5%
$1.4750 day average+30.1%
$1.43100 day average+26.5%
$1.42200 day average+25.7%
$1.2820 day average+13.3%
$1.24Swing high (May 29)+9.7%
$1.17Pivot R1+3.5%
$1.14Pivot+0.9%
$1.13Last close
$1.10Pivot S1−2.7%
$1.10Swing low (Jun 5)−2.7%
$0.8452 week low−25.7%
Indicators
RSI (14)35.18Weak, oversold below 30Neutral
MACD-0.04Below its signal lineBearish
Stochastic13.3Near the bottom of its rangeOversold
ADX (14)27.2Trending down
Williams %R-96.4Oversold below −80, overbought above −20Oversold
CCI (20)-95.5Oversold below −100, overbought above 100Neutral
Rate of change−22.6%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 11.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALZN

What happened before

See how ALZN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ALZN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ALZN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ALZN in the last 90 days.

Loading…

See today’s whale options flow across the market →

ALZN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲7 buying vs 3 selling
  • ▼Held by funds -0.6 pts
  • ▲Funds holding +4
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1511+36.4%
In funds' top 1000–
Held by funds28.2%28.8%−0.6 pts
New / increased4 / 31 / 2+133.3%
Reduced / sold out3 / 04 / 3−57.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALZN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALZN is in one of them and how their past ALZN trades turned out.

ALZN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALZN in an article yet. Here's the latest on the wider market.

About Alzamend Neuro

Alzamend Neuro is a clinical stage drug developer based in Atlanta, Georgia, focused on brain disorders. It is working on treatments for Alzheimer's disease, bipolar disorder, major depressive disorder and post traumatic stress disorder. Its lead candidate, AL001, is a form of lithium designed to treat these conditions, and it is in human clinical trials. Its target patients are people living with these illnesses.

Headquarters
Atlanta, GA